M. A. Varillas, Marta I. V. Brevedan, N. G. Gonzalez Vidal
{"title":"阿根廷氯沙坦钾片的药物等效性","authors":"M. A. Varillas, Marta I. V. Brevedan, N. G. Gonzalez Vidal","doi":"10.14227/dt290222pgc2","DOIUrl":null,"url":null,"abstract":"Losartan potassium (LOK) is an antihypertensive agent from the group of selective angiotensin AT1 receptor antagonists, widely used in the form of tablets for oral administration. The available data for BCS classification are confusing, though class III or IV are most likely. The quality attributes of solid oral dosage forms of LOK immediate-release tablets (50 mg) available in the Argentine pharmaceutical market were evaluated according to the Argentine Pharmacopoeia and United States Pharmacopeia (i.e., storage conditions information, price per tablet, average weight, assay, uniformity of dosage units, hardness, disintegration time, and in vitro dissolution). The dissolution efficiency (DE) results were compared using one way analysis of variance. All evaluated samples were within the acceptable limits for disintegration time, hardness, assay, uniformity of dosage units, and in vitro dissolution (in Stage 1). A statistically significant difference in DE was recorded for samples C, D, E, F, and G compared to the reference formulation (sample H). These samples had higher DE values than the reference; there were no statistically significant differences between the samples. Therefore, the evaluated samples of LOK from the Argentine market can be considered pharmaceutical equivalents.","PeriodicalId":11380,"journal":{"name":"Dissolution Technologies","volume":"45 1","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmaceutical Equivalence of Losartan Potassium Tablets in Argentina\",\"authors\":\"M. A. Varillas, Marta I. V. Brevedan, N. G. Gonzalez Vidal\",\"doi\":\"10.14227/dt290222pgc2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Losartan potassium (LOK) is an antihypertensive agent from the group of selective angiotensin AT1 receptor antagonists, widely used in the form of tablets for oral administration. The available data for BCS classification are confusing, though class III or IV are most likely. The quality attributes of solid oral dosage forms of LOK immediate-release tablets (50 mg) available in the Argentine pharmaceutical market were evaluated according to the Argentine Pharmacopoeia and United States Pharmacopeia (i.e., storage conditions information, price per tablet, average weight, assay, uniformity of dosage units, hardness, disintegration time, and in vitro dissolution). The dissolution efficiency (DE) results were compared using one way analysis of variance. All evaluated samples were within the acceptable limits for disintegration time, hardness, assay, uniformity of dosage units, and in vitro dissolution (in Stage 1). A statistically significant difference in DE was recorded for samples C, D, E, F, and G compared to the reference formulation (sample H). These samples had higher DE values than the reference; there were no statistically significant differences between the samples. Therefore, the evaluated samples of LOK from the Argentine market can be considered pharmaceutical equivalents.\",\"PeriodicalId\":11380,\"journal\":{\"name\":\"Dissolution Technologies\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dissolution Technologies\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.14227/dt290222pgc2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dissolution Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14227/dt290222pgc2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Pharmaceutical Equivalence of Losartan Potassium Tablets in Argentina
Losartan potassium (LOK) is an antihypertensive agent from the group of selective angiotensin AT1 receptor antagonists, widely used in the form of tablets for oral administration. The available data for BCS classification are confusing, though class III or IV are most likely. The quality attributes of solid oral dosage forms of LOK immediate-release tablets (50 mg) available in the Argentine pharmaceutical market were evaluated according to the Argentine Pharmacopoeia and United States Pharmacopeia (i.e., storage conditions information, price per tablet, average weight, assay, uniformity of dosage units, hardness, disintegration time, and in vitro dissolution). The dissolution efficiency (DE) results were compared using one way analysis of variance. All evaluated samples were within the acceptable limits for disintegration time, hardness, assay, uniformity of dosage units, and in vitro dissolution (in Stage 1). A statistically significant difference in DE was recorded for samples C, D, E, F, and G compared to the reference formulation (sample H). These samples had higher DE values than the reference; there were no statistically significant differences between the samples. Therefore, the evaluated samples of LOK from the Argentine market can be considered pharmaceutical equivalents.
期刊介绍:
Dissolution Technologies is a peer reviewed quarterly
publication reporting ongoing, useful information on
dissolution testing of pharmaceuticals. It provides an
international forum for dissolution analysts to receive
and exchange information on various dissolution topics.
Dissolution Technologies welcomes submissions related
to dissolution, in vitro release, and disintegration testing.
These topics should be the major focus of the article.
Do not submit articles where the focus is formulation
development with dissolution testing as one of many
tests.